Dexamethasone pretreatment alleviates intestinal ischemia-reperfusion injury.
BACKGROUND
Activated mast cells are involved in the pathogenesis of intestinal ischemia-reperfusion (I/R)-related injury. Dexamethasone has been widely used to protect organs from I/R injury. This study was conducted to investigate the impact of treatment with dexamethasone at different stages of the II/R process on mast cell infiltration and activity and intestinal injury.


METHODS
Kunming mice were randomized and subjected to a sham surgery or the II/R induction by clamping the superior mesenteric artery for 30 min and then reperfusion. During the II/R induction, the mice were treated intravenously with dexamethasone (10 mg/kg) for 30 min before ischemia (pretreatment group), at 5 min after clamping the superior mesenteric artery (isc-treatment group), or at the beginning of perfusion (rep-treatment group), respectively. The levels of intestinal injury, mast cell infiltration and activity, tumor necrosis factor α (TNFα) and myeloperoxidase (MPO) activity in the intestines, and mouse survival rates were measured.


RESULTS
The death rates, levels of intestinal injury, mast cell infiltration and activity, and tumor necrosis factor α and myeloperoxidase activity in the intestinal tissues from the II/R group were similar to those from the isc-treatment and rep-treatment groups of mice and were significantly higher than those from the sham group. In contrast, pretreatment with dexamethasone significantly mitigated the II/R-induced mast cell infiltration and activity, inflammation, and intestinal injury and reduced the death rates in mice.


CONCLUSIONS
Pretreatment with dexamethasone inhibits II/R injury by reducing mast cell-related inflammation in mice.
Department of Anesthesiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Department of Anesthesiology, Guangzhou Women and Children's Medical Center, Guangzhou, China.
Wenhua
W
Zhang
Jibin
J
Xing
Dezhao
D
Liu
Xiaoliang
X
Gan
Wanling
W
Gao
Ziqing
Z
Hei
D000208:Acute Disease; D000818:Animals; D003907:Dexamethasone / Q000494:pharmacology*; D004195:Disease Models, Animal; D005938:Glucocorticoids / Q000494:pharmacology; D007410:Intestinal Diseases / Q000188:drug therapy* / Q000276:immunology* / Q000401:mortality; D008297:Male; D008407:Mast Cells / Q000187:drug effects* / Q000276:immunology; D051379:Mice; D008815:Mice, Inbred Strains; D011897:Random Allocation; D044464:Receptor, PAR-2 / Q000378:metabolism; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000276:immunology* / Q000401:mortality; D015996:Survival Rate; D013997:Time Factors; D053802:Tryptases / Q000378:metabolism
D005938:Glucocorticoids; D044464:Receptor, PAR-2; D003907:Dexamethasone; C509222:Tpsab1 protein, mouse; D053802:Tryptases
Dexamethasone; Intestine; Ischemia–reperfusion injury; Mast cell